Clinical trialPhase 2Terminated
Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
Nivolumab, Ipilimumab and Radiation in Combination With Influenza Vaccine in Patients With Pancreatic Cancer (INFLUENCE)
- Outcome
- Stopped earlyBased on the precpecified interim analysis the predictive probability was below 10% for the prespecified endpoint. (Other)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 5 November 2021
- Expected end
- 19 October 2023
- Enrollment
- 19 participants
- Sites
- 1
- Primary outcomes
- Objective response rate (ORR)
- Sponsor
- Other
- Results posted
- No
- Last update
- 28 May 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try